{"id":7027,"date":"2024-08-06T13:52:03","date_gmt":"2024-08-06T06:52:03","guid":{"rendered":"https:\/\/thaipropertynews.com\/feeds\/?p=7027"},"modified":"2024-08-06T13:52:03","modified_gmt":"2024-08-06T06:52:03","slug":"obio-technology-congratulates-on-the-first-clinical-gene-editing-therapy-to-treat-an-overseas-patient-in-china-by-correctsequence-therapeutics","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=7027","title":{"rendered":"OBiO Technology Congratulates on The First Clinical Gene Editing Therapy to Treat An Overseas Patient in China by CorrectSequence Therapeutics"},"content":{"rendered":"

SHANGHAI<\/span>, Aug. 6, 2024 \/PRNewswire\/ — Recently, CorrectSequence <\/span>Therapeutics Co., Ltd. (Correctseq) announced a significant milestone in their base editing therapy CS-101 for transfusion-dependent \u03b2-thalassemia. Utilizing their pioneering transformer Base Editor (tBE), Correctseq has successfully cured the first overseas patient with transfusion-dependent \u03b2-thalassemia in a clinical trial in collaboration with the First Affiliated Hospital of Guangxi Medical University. The patient has achieved a sustained transfusion-free status for over two months, with the hemoglobin level stabilized at above 120 g\/L. As a result, the patient has been able to resume a normal life. This milestone marks China’s<\/span> first documented report of an overseas patient being clinically cured through gene editing therapy.\u00a0OBiO\u00a0Technology\u00a0(Shanghai<\/span>)\u00a0Corp.,\u00a0Ltd. (OBiO Technology) extends its heartfelt congratulations and best wishes to the patient who has been cured, and warmly congratulates the partner Correctseq on this significant progress.<\/span><\/p>\n

\n

<\/a>
<\/span><\/p>\n<\/div>\n

The Phase I clinical trial for the treatment of \u03b2-thalassemia with CS-101 is proceeding steadily. In tandem, a clinical trial targeting sickle cell disease (SCD) with CS-101 are in active preparation. A global recruitment program for SCD patients is recently launched.\u00a0<\/span><\/p>\n

OBiO Technology is a leading CDMO company specializing in cell and gene therapy in China<\/span>, equipped with 15 GMP vector production lines and 20 GMP cell therapy production lines. As a reliable partner with Correctseq, OBiO Technology has provided solid support for CS-101, including process development, analytical development, production and IND filling services. OBiO Technology celebrates the significant achievements made in treating patients with CS-101, affirming the successful collaboration between the two companies. Driven by innovation and united in purpose, we believe our close partnership will bring hope and a brighter future to patients worldwide!<\/p>\n

About CorrectSequence Therapeutics<\/p>\n

CorrectSequence TherapeuticsTM\u00a0(CorrectseqTM), is a clinical-stage biotech company employing its proprietary transformer Base Editor (tBE) to pioneer next-generation gene editing therapies. Our leading pipeline candidate, CS-101, utilizing innovative base editor targeting HBG, curing \u03b2-hemoglobinopathies, has obtained IND approval from the China NMPA. Clinical data demonstrate its superior performance. Proof-of-concept (POC) data in mice for\u00a0in vivo\u00a0pipelines using tBE-editing therapies via lipid nanoparticle (LNP) delivery are available, including targets for metabolic dysfunction and associated diseases.\u00a0Ex vivo\u00a0multiplex editing of T cells on multiple targets simultaneously preserved T cell growth and function\u00a0in vivo\u00a0compared to non-edited cells, establishing tBE as the ideal gene editing tool for the next-generation cell therapy development. We are developing multiple pipeline programs targeting genetic diseases, metabolic disorders, and cardiovascular diseases.<\/p>\n

Please refer to our homepage for more information about the tBE and its therapeutics applications at\u00a0www.correctsequence.com<\/a><\/p>\n

About OBiO\u00a0Technology<\/p>\n

Established in 2013,\u00a0OBiO Technology\u00a0is a pioneering Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) in gene and cell therapy, offering comprehensive solutions. Our unwavering dedication ensures high-quality\u00a0CRO and CDMO services\u00a0for consumers worldwide across preclinical, IND, clinical, and commercial stages, including plasmids, mRNA, AAV, LVV, Ad viral vectors, cell therapy (CAR-T, NK, Treg, iPSCs), exosomes, and cutting-edge technologies like inducible viral vector packaging, ultralow endotoxin processes, and AAVneO screening for tissue-specific AAV variants. Guided by our mission\u00a0“Enable Gene Therapy for Better Lives”,\u00a0we are dedicated to delivering top-tier services globally. From bench to clinic, we are committed to advancing your product and benefiting populations worldwide.<\/p>","protected":false},"excerpt":{"rendered":"

<\/p>\n

SHANGHAI<\/span>, Aug. 6, 2024 \/PRNewswire\/ — Recently, CorrectSequence <\/span>Therapeutics Co., Ltd. (Correctseq) announced a significant milestone in their base editing therapy CS-101 for transfusion-dependent \u03b2-thalassemia. Utilizing their pioneering transformer Base Editor (tBE), Correctseq has successfully cured the first overseas patient with transfusion-dependent \u03b2-thalassemia in a clinical trial in collaboration with the First Affiliated Hospital of Guangxi Medical University. The patient has achieved a sustained transfusion-free status for over two months, with the hemoglobin level stabilized at above 120 g\/L. As a result, the patient has been able to resume a normal life. This milestone marks China’s<\/span> first documented report of an overseas patient being clinically cured through gene editing therapy.\u00a0OBiO\u00a0Technology\u00a0(Shanghai<\/span>)\u00a0Corp.,\u00a0Ltd. (OBiO Technology) extends its heartfelt congratulations and best wishes to the patient who has been cured, and warmly congratulates the partner Correctseq on this significant progress.<\/span><\/p>\n

\n

<\/a>
<\/span><\/p>\n<\/div>\n

The Phase I clinical trial for the treatment of \u03b2-thalassemia with CS-101 is proceeding steadily. In tandem, a clinical trial targeting sickle cell disease (SCD) with CS-101 are in active preparation. A global recruitment program for SCD patients is recently launched.\u00a0<\/span><\/p>\n

OBiO Technology is a leading CDMO company specializing in cell and gene therapy in China<\/span>, equipped with 15 GMP vector production lines and 20 GMP cell therapy production lines. As a reliable partner with Correctseq, OBiO Technology has provided solid support for CS-101, including process development, analytical development, production and IND filling services. OBiO Technology celebrates the significant achievements made in treating patients with CS-101, affirming the successful collaboration between the two companies. Driven by innovation and united in purpose, we believe our close partnership will bring hope and a brighter future to patients worldwide!<\/p>\n

About CorrectSequence Therapeutics<\/p>\n

CorrectSequence TherapeuticsTM\u00a0(CorrectseqTM), is a clinical-stage biotech company employing its proprietary transformer Base Editor (tBE) to pioneer next-generation gene editing therapies. Our leading pipeline candidate, CS-101, utilizing innovative base editor targeting HBG, curing \u03b2-hemoglobinopathies, has obtained IND approval from the China NMPA. Clinical data demonstrate its superior performance. Proof-of-concept (POC) data in mice for\u00a0in vivo\u00a0pipelines using tBE-editing therapies via lipid nanoparticle (LNP) delivery are available, including targets for metabolic dysfunction and associated diseases.\u00a0Ex vivo\u00a0multiplex editing of T cells on multiple targets simultaneously preserved T cell growth and function\u00a0in vivo\u00a0compared to non-edited cells, establishing tBE as the ideal gene editing tool for the next-generation cell therapy development. We are developing multiple pipeline programs targeting genetic diseases, metabolic disorders, and cardiovascular diseases.<\/p>\n

Please refer to our homepage for more information about the tBE and its therapeutics applications at\u00a0www.correctsequence.com<\/a><\/p>\n

About OBiO\u00a0Technology<\/p>\n

Established in 2013,\u00a0OBiO Technology\u00a0is a pioneering Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) in gene and cell therapy, offering comprehensive solutions. Our unwavering dedication ensures high-quality\u00a0CRO and CDMO services\u00a0for consumers worldwide across preclinical, IND, clinical, and commercial stages, including plasmids, mRNA, AAV, LVV, Ad viral vectors, cell therapy (CAR-T, NK, Treg, iPSCs), exosomes, and cutting-edge technologies like inducible viral vector packaging, ultralow endotoxin processes, and AAVneO screening for tissue-specific AAV variants. Guided by our mission\u00a0“Enable Gene Therapy for Better Lives”,\u00a0we are dedicated to delivering top-tier services globally. From bench to clinic, we are committed to advancing your product and benefiting populations worldwide.<\/p>\n

<\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-7027","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/7027","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=7027"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/7027\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=7027"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=7027"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=7027"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}